Anti-AMP Activated Protein Kinase gamma1 (AMPK g1) Polyclonal Antibody

Cat# A1475-07-100ul

Size : 100ul

Brand : US Biological

Request more information



A1475-07 AMP Activated Protein Kinase gamma1 (AMPK g1)

Clone Type
Polyclonal
Host
rabbit
Source
human
Swiss Prot
P54619
Isotype
IgG
Grade
Affinity Purified
Applications
WB
Crossreactivity
Hu Mk
Shipping Temp
Blue Ice
Storage Temp
-20°C

AMP-activated protein kinase (AMPK) is highly conserved from yeast to plants and animals and plays a key role in the regulation of energy homeostasis 1). AMPK is a heterotrimeric complex composed of a catalytic a subunit and regulatory b and g subunits, each of which is encoded by two or three distinct genes a1, 2; b1, 2; g1, 2, 3) (2). The kinase is activated by an elevated AMP/ATP ratio due to cellular and environmental stress, such as heat shock, hypoxia and ischemia (1). Tumor suppressor LKB1, in association with accessory proteins STRAD and MO25, phosphorylates AMPK at Thr172 at the activation loop, and this phosphorylation is required for AMPK activation (3–5). AMPKa is also phosphorylated at Thr258 and Ser485 for a1; Ser491 for a2). The upstream kinase and the biological significance of these phosphorylation events have yet to be elucidated (6). The b1 subunit is posttranslationally modified by myristoylation and multi-site phosphorylation including Ser24/25, Ser96, Ser101, Ser108, and Ser182 (6,7). Phosphorylation at Ser108 of the b1 subunit seems to be required for the activation of|AMPK enzyme, while phosphorylation at Ser24/25 and Ser182 affects AMPK localization (7). Several mutations in AMPKg subunits have been identified, most of which are located in the putative AMP/ATP binding sites (CBS or Bateman domains). Mutations at these sites lead to|reduction of AMPK activity and cause glycogen accumulation in heart or skeletal muscle (1,2). Accumulating evidence indicates that AMPK not only regulates the metabolism of fatty acids and glycogen, but also modulates protein synthesis and cell growth through EF2 and TSC2/mTOR pathways, as well as blood flow via eNOS/nNOS (1).||Applications: |Suitable for use in Western Blot. Other applications not tested.||Recommended Dilution:|Western Blot: 1:1000|Optimal dilutions to be determined by the researcher.||Storage and Stability:|May be stored at 4°C for short-term only. For long-term storage and to avoid repeated freezing and thawing, aliquot. Store at -20°C. Aliquots are stable for at least 12 months at -20°C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Applications
Product Type: Pab|Isotype: IgG|Host: rabbit|Source: human|Concentration: Not determined|Form: Supplied as a liquid in 10mM sodium HEPES, pH 7.5, 150mM sodium chloride, 100ug/ml BSA, 50% glycerol.|Purity: Purified by Protein A and peptide affinity chromatography.|Immunogen: Synthetic peptide corresponding to residues near the N-terminus of human AMPKg1. |Specificity: Detects endogenous levels of human AMPKg1 protein. Species Crossreactivity: monkey||Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.
Immunogen
Synthetic peptide corresponding to residues near the N-terminus of human AMPKg1.
Form
Supplied as a liquid in 10mM sodium HEPES, pH 7.5, 150mM sodium chloride, 100ug/ml BSA, 50% glycerol.
Purity
Purified by Protein A and peptide affinity chromatography.
Specificity
Detects endogenous levels of human AMPKg1 protein. Species Crossreactivity: monkey
References
(1) Hardie, D.G. (2004) J. Cell Sci. 117, 5479-5487. (2) Carling, D. (2004) Trends Biochem. Sci. 29, 18–24. (3) Hawley, S.A. et al. (1996) J. Biol. Chem. 271, 27879–27887. (4) Lizcano, J.M. et al. (2004) EMBO J. 23, 833–843. (5) Shaw, R. et al. (2004) Proc. Natl. Acad. Sci. USA 101, 3329–3335. (6) Woods, A. et al. (2003) J. Biol. Chem. 278, 28434–28442. (7) Warden, S.M. et al. (2001) Biochem. J. 354, 275–283.